PMC5836197_01
a Sharply delineated erythematosquamous psoriatic plaques of the right leg before infliximab therapy in May 2008. b After the fourth infusion of infliximab at a dose of 5 mg/kg in February 2009, the psoriatic lesions on the right leg had almost disappeared.
crn-0010-0012-g01.jpg
PMC5836197_01_crn-0010-0012-g01.jpg
F1
Two months into therapy joint and skin symptoms were greatly improved, with a reduction of the Psoriasis Area and Severity Index from 23.4 prior to infliximab therapy (Fig. 1a) to 3.9, and the therapeutic effect could be maintained throughout the following months of therapy (Fig. 1b).
a, b Magnetic resonance images of the brain in February 2009. T2-weighted images show a lesion in the left peritrigonal region without contrast agent enhancement (arrows) indicative of an inflammatory lesion.
crn-0010-0012-g02.jpg
PMC5836197_01_crn-0010-0012-g02.jpg
F2
MRI scans in February 2009 revealed a lesion in the left peritrigonal region (Fig. 2a, b, arrows) which showed no contrast enhancement, but due to its localization and shape, an inflammatory process was most likely.